Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 7, keine Gesamtzahl für „Simponi“
Suchtreffer
Begriffe & Kennungen
Simponi · 4.8 · In the controlled and uncontrolled period of pivotal trials with a median follow-up of up to 3 years, malignan
Eintrag öffnenSimponi · 4.8 · In the controlled and uncontrolled period of pivotal trials with a median follow-up of up to 3 years, malignan
Eintrag öffnenSimponi · 4.8 · In the controlled and uncontrolled period of pivotal trials with a median follow-up of up to 3 years, malignan
Eintrag öffnenSimponi · 4.8 · In the controlled and uncontrolled periods of pivotal trials with a median follow-up of up to 3 years, non-mel
Eintrag öffnenSimponi · 4.8 · In the controlled and uncontrolled periods of pivotal trials with a median follow-up of up to 3 years, non-mel
Eintrag öffnenSimponi · 4.8 · In the controlled and uncontrolled periods of pivotal trials with a median follow-up of up to 3 years, non-mel
Eintrag öffnenSimponi · 4.8 · In the controlled and uncontrolled periods of pivotal trials with a median follow-up of up to 3 years, non-mel
Eintrag öffnenSimponi · 4.8 · In the controlled and uncontrolled periods of pivotal trials with a median follow-up of up to 3 years, non-mel
Eintrag öffnenSimponi · 4.8 · In the controlled period of RA and AS pivotal trials, ALT elevations ≥ 5 x ULN were uncommon and seen in more
Eintrag öffnenSimponi · 4.8 · In the controlled period of RA and AS pivotal trials, ALT elevations ≥ 5 x ULN were uncommon and seen in more
Eintrag öffnenSimponi · 4.8 · In the controlled period of RA and AS pivotal trials, ALT elevations ≥ 5 x ULN were uncommon and seen in more
Eintrag öffnenSimponi · 4.8 · In the controlled period of RA and AS pivotal trials, ALT elevations ≥ 5 x ULN were uncommon and seen in more
Eintrag öffnenSimponi · 4.8 · In the controlled period of RA and AS pivotal trials, ALT elevations ≥ 5 x ULN were uncommon and seen in more
Eintrag öffnenSimponi · 4.8 · In the controlled period of RA, PsA, AS, and nr-Axial SpA trials, serious infections were observed in 1.2% of
Eintrag öffnenSimponi · 4.8 · In the controlled period of RA, PsA, AS, and nr-Axial SpA trials, serious infections were observed in 1.2% of
Eintrag öffnenSimponi · 4.8 · In the controlled period of RA, PsA, AS, and nr-Axial SpA trials, serious infections were observed in 1.2% of
Eintrag öffnenSimponi · 4.8 · In the controlled period of RA, PsA, AS, and nr-Axial SpA trials, serious infections were observed in 1.2% of
Eintrag öffnenSimponi · 4.8 · In the controlled period of RA, PsA, AS, and nr-Axial SpA trials, serious infections were observed in 1.2% of
Eintrag öffnenSimponi · 4.8 · In the controlled period of pivotal trials, infections were observed in 23.0% of golimumab-treated patients (i
Eintrag öffnenSimponi · 4.8 · In the controlled period of pivotal trials, infections were observed in 23.0% of golimumab-treated patients (i
Eintrag öffnen